Abstract: Provided herein are compounds for inhibiting monoacylglycerol lipase (MAGL), and related methods of making and using the compounds.

Abstract: Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment and/or management of pain and related conditions, including post-operative pain, pain incident to an incision or wound, chronic pain, severe pain, moderate to severe chronic pain, or chronic non-cancer pain, the method comprising administering to the subject a therapeutically effective amount of a compound.

Abstract: Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment of anxiety and related conditions, including Generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety disorder, anxious depression, and phobias, the methods comprising administering to the subject a therapeutically effective amount of a compound.

Abstract: Provided herein are compounds for inhibiting monoacylglycerol lipase (MAGL), and related methods of making and using the compounds.

Abstract: Provided herein are 1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-yl methanone compounds substituted with aryl and pyrazolyl moieties, further substituted, for inhibiting monoacylglycerol lipase (MAGL), utilized in the treatment of a MAGL-mediated disease or disorder i.e., neurodegenerative diseases, pain, and inflammatory diseases or conditions, as well as cancer, and related methods of making and using the compounds.

Abstract: Provided herein are compounds for inhibiting monoacylglycerol lipase (MAGL), and related methods of making and using the compounds.

Abstract: Provided herein are compounds that inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

Abstract: Isotopically labeled formaldehyde (*C§H2O) is prepared from labeled methyl iodide (*C§H3I) by reaction with an oxygen nucleophile having a pendant leaving group. The mild and efficient reaction conditions result in good yields of *C§H2O with little or no *C isotopic dilution. The simple, efficient production of 11CH2O is described. The use of the 11CH2O for the formation of positron emission tomography tracer compounds is described. The reaction can be incorporated into automated equipment available to radiochemistry laboratories. The isotopically labeled formaldehyde can be used in a variety of reactions to provide radiotracer compounds for imaging studies as well as for scintillation counting and autoradiography.

Abstract: Isotopically labeled formaldehyde (*C§H2O) is prepared from labeled methyl iodide (*C§H3I) by reaction with an oxygen nucleophile having a pendant leaving group. The mild and efficient reaction conditions result in good yields of *C§H2O with little or no *C isotopic dilution. The simple, efficient production of 11CH2O is described. The use of the 11CH2O for the formation of positron emission tomography tracer compounds is described. The reaction can be incorporated into automated equipment available to radiochemistry laboratories. The isotopically labeled formaldehyde can be used in a variety of reactions to provide radiotracer compounds for imaging studies as well as for scintillation counting and autoradiography.